New price gets Clovis’ PARP inhibitor on the CDF
Lynparza first in class approved in breast cancer
Impressed by survival data, FDA hastens review in expanded patient group
EU regulators recommend PARP inhibitor Zejula
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.